First-line Immunotherapy Still Elusive in Advanced Liver Cancer First-line Immunotherapy Still Elusive in Advanced Liver Cancer
First-line immunotherapy remains elusive for patients with hepatocellular carcinoma (HCC), but early results look good for a combination with bevacizumab.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Health | Hematology | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Urology & Nephrology